Table 1.
Characteristics of individuals within the HIV transmission network and persons with diagnosed HIV participating in syringe services program, Miami, FL, 2018
| Individuals with HIV seroconversion (n = 7) |
Primary epidemiologic linksa (n = 10) |
IDEA participants living with HIVa (n = 32) |
|
|---|---|---|---|
| Demographics | |||
| Age—median(range) | 39 (27–58) | 33 (25–57) | 39.5 (25–69) |
| Sex—n(%) | |||
| Male | 6 (85.7) | 4 (40.0) | 17 (53.1) |
| Female | 1 (14.3) | 6 (60.0) | 15 (46.9) |
| Race/ethnicity—n(%) | |||
| non-Hispanic White | 5 (71.4) | 6 (60.0) | 13 (40.6) |
| non-Hispanic Black | 0 | 1 (10.0) | 8 (25.0) |
| Multi-race | 1 (14.3) | 0 | 1 (3.1) |
| Hispanic | 1 (14.3) | 1 (10.0) | 10 (31.3) |
| Unknown | 0 | 2 (20.0) | 0 |
| Homeless | |||
| Yes | 7 (100) | 4 (40.0) | 9 (28.1) |
| No | 0 | 4 (40.0) | 23 (71.9) |
| Unknown | 0 | 2 (20.0) | 0 |
| Self-Reported HIV exposure riskb | |||
| Heterosexual contact | 1 (14.3) | 3 (37.5) | 7 (21.9) |
| IDU | 5 (71.4) | 4 (50.0) | 14 (43.8) |
| MSM | 0 | 1 (12.5) | 4 (12.5) |
| MSM/IDU | 1 (14.3) | 0 | 7 (21.9) |
| Syringe sharing | |||
| Yes | 6 (85.7) | 5 (50.0) | 6 (18.8) |
| No | 1 (14.3) | 0 | 1 (3.1) |
| Unknown | 0 | 5 (50.0) | 25 (78.1) |
| Reported drug use | |||
| Heroin | 7 (100) | 5 (50.0) | 6 (18.8) |
| Cocaine | 5 (71.4) | 4 (40.0) | 6 (18.8) |
| Methamphetamine | 1 (14.3) | 2 (20.0) | 3 (9.4) |
| Crack | 1 (14.3) | 5 (50.0) | 6 (18.8) |
| Speedball | 2 (28.6) | 2 (20.0) | 2 (6.3) |
| HIV clinical characteristics | |||
| Baseline viral load (copies/mL)—median(range) |
173,691 (477–684,490) |
37,473 (< 20–548,046) |
13,207 (< 20–1,280,000) |
| Baseline CD4 count—median(range) | 458 (305–885) | 340 (143–914) | 456 (8–1562) |
| Ever virally suppressed | |||
| Yes | 7 (100.0) | 4 (50.0) | 23 (71.9) |
| No | 0 | 4 (50.0) | 9 (28.1) |
| Currently virally suppressedc | |||
| Yes | 7 (100.0) | 3 (37.5) | 17 (53.1) |
| No | 0 | 5 (62.5) | 15 (46.9) |
| Time to linkage to care—mean days(range) | 20 (0–49) | – | – |
| Time to viral suppression—mean(range) | 70 (14–158) | – | – |
| Time to in-care viral suppression—mean days(range) | 50 (14–125) | 39 (0–96) | 874 (0–6168) |
| HIV genotype—n(%) | |||
| Yes | 5 (71.4) | 3 (37.5) | 18 (56.3) |
| No | 2 (28.6) | 5 (62.5) | 14 (43.7) |
| Hepatitis C antibodyd—n(%) | |||
| Positive before 2018 | 4 (57.1) | 5 (62.5) | 18 (56.3) |
| Positive in 2018 | 3 (42.9) | 4 (50.0) | 7 (21.9) |
| Unknown | 3 (42.9) | 1 (1.3) | 11 (34.4) |
| Hepatitis C NATd—n(%) | |||
| Positive before 2018 | 1 (14.3) | 3 (37.5) | 8 (25.0) |
| Positive in 2018 | 2 (28.6) | 3 (37.5) | 5 (15.6) |
| Unknown | 4 (57.1) | 4 (50.0) | 19 (59.4) |
| Syphilisd—n(%) | |||
| Positive before 2018 | 2 (28.6) | 3 (37.5) | 12 (37.5) |
| Positive in 2018 | 1 (14.3) | 2 (25.0) | 5 (15.6) |
| Unknown | 4 (57.1) | 5 (62.5) | 18 (56.3) |
IDU injection drug use, MSM male sex with males
aColumns are not mutually exclusive, n = 7 individuals are represented in both groups
bTwo individuals from the primary epidemiologic links category were excluded from the self-reported HIV exposure risk as they were not known to have HIV
cVirally suppressed as of December 20, 2018
dRows are not mutually exclusive, individuals with reported labs could have had labs prior to 2018, in 2018 or both